A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
about
A nonimmunosuppressant approach on Asia psoriasis subjects: 5-year followup and 11-year data analysisRecent Insights Into the Genetics of Inflammatory Bowel DiseaseWnt5a exhibits layer-specific expression in adult skin, is upregulated in psoriasis, and synergizes with type 1 interferonThe interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivoThe biological functions of T helper 17 cell effector cytokines in inflammationIL-17RC: a partner in IL-17 signaling and beyondUstekinumabGenome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathwaysUstekinumab for the treatment of Crohn's disease: can it find its niche?β-catenin/TCF-1 pathway in T cell development and differentiationProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPolymer-conjugated inhibitors of tumor necrosis factor-α for local control of inflammationGranuloma formation in pulmonary sarcoidosisHydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeuticsInterleukin-23: as a drug target for autoimmune inflammatory diseasesMucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapyNew targets in psoriatic arthritisNovel insights into the role of immune cells in skin and inducible skin-associated lymphoid tissue (iSALT)Induction of intestinal Th17 cells by segmented filamentous bacteriaMast cells and neutrophils release IL-17 through extracellular trap formation in psoriasisIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisReview of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasisApilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasisPsoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalkInflammatory bowel diseaseDevelopment, cytokine profile and function of human interleukin 17-producing helper T cellsUstekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvementHuman interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cellsrs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variantsThe synovio-entheseal complex in enthesoarthritis.IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac diseaseGenome-wide association scan in psoriasis: new insights into chronic inflammatory disease.Biologics in dermatologic therapy - an update.Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Genetic-based prediction of disease traits: prediction is very difficult, especially about the futureUstekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models.Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis.Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice.
P2860
Q21296668-2938EF09-9D07-4EB5-AFB0-5261805E1F00Q22250935-E3D8BD03-B5D0-4B11-A24B-4A6541BE2345Q24319773-0EC6BFCC-CEB4-4621-B769-854CC1A1C110Q24600773-60B69685-7E1E-4EFF-ABC2-8EF321CA0E70Q24614431-1A8B0217-1AA7-4B50-8FF0-819715CD147FQ24629783-1938C088-3A1F-45E2-82B9-68EBDCC65704Q24651927-D655222D-329D-4D1C-B049-09B986809DF9Q24653432-002FE2A0-3EC7-41E7-992E-5910AC337B4CQ26771890-BD769A94-1D38-4E6F-8944-21ABF64E71A0Q26821842-DD5F0EF6-2CE3-4205-8D7F-4ECEF3EAC47DQ26825174-C1AFF489-6BDD-4717-A7C2-1C0D5524BAE5Q26827714-607E3EC3-E45D-44ED-90D4-7245DED2F334Q26852346-5813318B-9EA6-4FFA-ACC6-6720755F57A0Q26863703-1DE21AB5-7713-405F-A040-030E352B1BB9Q27004640-08C0E100-E80B-4201-85A3-DFF821F6E147Q27009502-BB7494DC-21BB-418E-B582-C8D3818B1E0CQ27010562-CB5FEEEE-D94F-4260-BE02-9A6DCF26B67FQ28069592-7FB6B266-C4A6-4416-BA63-CDED30D85FBEQ28081241-CDA3F600-39DF-40AD-A33A-2A62FC8F85BCQ28131638-1FB1C75C-B2DF-4BB9-A305-8BC12B9BD8C3Q28238414-C8A4A3AF-E61D-4A51-9418-413C6CDCA3ECQ28268370-875B6D17-CC3A-49D6-ACE0-EDF47BBDE777Q28280687-3FC82279-A2AA-48DF-BBF2-9DAAE8B4A7A2Q28482161-0282961B-A786-4D1B-93F7-A12C697B16C2Q28587108-3A1CFF34-2C00-459C-BA73-2F87DF998C90Q29616286-4654F7B3-BAF5-48B9-B96A-60FB642C5E9FQ29617131-54362DFF-36F8-43BE-A901-E958214AF3D7Q30620977-332D5FAB-FABB-4BC2-AFA3-3A490F4AC442Q31151707-A829B7D5-98B3-4A26-9EAD-5153F7ED037AQ33296981-2400EDF8-625F-437C-A330-D32BB4B6D374Q33360030-9E915DFB-08F5-4D78-B612-D0396E95A781Q33403660-9DC94405-CB22-4A03-9543-BDEA87275B37Q33579359-3EE59DB8-4486-4218-B231-579951A8DDCBQ33607620-23E52DD5-371F-4C00-B7C5-EF655D5A0571Q33625546-0BA6BAAC-468B-48AE-9BD6-764AF36D4670Q33693846-FB056E7F-F30F-425F-B8E3-4306E6781D80Q33710915-47F2B170-4EC6-4440-B843-7FCD00546453Q33725862-19D99642-494D-4026-9EA8-B997248A056AQ33760897-9B6F5E71-9AA9-4549-8665-FD5DF88DA11CQ33761544-762DD57B-BE34-4748-8766-34E046846660
P2860
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@ast
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@en
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@nl
type
label
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@ast
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@en
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@nl
prefLabel
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@ast
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@en
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@nl
P2093
P356
P1476
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
@en
P2093
CNTO 1275 Psoriasis Study Group
Craig Leonardi
Cynthia Guzzo
Gerald G Krueger
Lisa T Dooley
Mark Lebwohl
Newman Yeilding
Richard G Langley
Yuhua Wang
P304
P356
10.1056/NEJMOA062382
P407
P577
2007-02-01T00:00:00Z